Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward B Garon

Showing results (41-50 of 204) with videos related to

Pageof 21
Sort By:
Lung Cancer (Amsterdam, Netherlands)|January 15, 2022
What is the current role of immunotherapy in EGFR mutant advanced NSCLC?Maria A Velez, Hsin Hsiang Clarence Tsai, David B Shackelford, et al.
Journal of Cardiothoracic Surgery|March 1, 2011
High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessationCindy Mong, Edward B Garon, Clark Fuller, et al.
Leukemia Research|October 10, 2006
Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cellsEdward B Garon, Laura Marcu, Quang Luong, et al.
Lung Cancer (Amsterdam, Netherlands)|December 9, 2023
Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A reviewMargarita Majem, Ethan Basch, David Cella, et al.
Frontiers in Oncology|September 21, 2023
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature reviewEdward B Garon, Carla Visseren-Grul, Maria Teresa Rizzo, et al.
Molecular & Cellular Proteomics : MCP|November 19, 2011
Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometryHua Xiao, Lei Zhang, Hui Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancerMaurice Pérol, Katherine B Winfree, Gebra Cuyun Carter, et al.
Oncotargets and Therapy|December 13, 2016
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancerEdward B Garon, Jeffrey D Neidhart, Nashat Y Gabrail, et al.
Lung Cancer Management|May 8, 2013
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancerNadiyah Kazmi, Diana C Márquez-Garbán, Lilia Aivazyan, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2022
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationshipKazuhiko Nakagawa, Edward B Garon, Ling Gao, et al.
Pageof 21

Showing results (41-50 of 204) with videos related to

Sort By:
Pageof 21
Lung Cancer (Amsterdam, Netherlands)|January 15, 2022
What is the current role of immunotherapy in EGFR mutant advanced NSCLC?Maria A Velez, Hsin Hsiang Clarence Tsai, David B Shackelford, et al.
Journal of Cardiothoracic Surgery|March 1, 2011
High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessationCindy Mong, Edward B Garon, Clark Fuller, et al.
Leukemia Research|October 10, 2006
Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cellsEdward B Garon, Laura Marcu, Quang Luong, et al.
Lung Cancer (Amsterdam, Netherlands)|December 9, 2023
Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A reviewMargarita Majem, Ethan Basch, David Cella, et al.
Frontiers in Oncology|September 21, 2023
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature reviewEdward B Garon, Carla Visseren-Grul, Maria Teresa Rizzo, et al.
Molecular & Cellular Proteomics : MCP|November 19, 2011
Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometryHua Xiao, Lei Zhang, Hui Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancerMaurice Pérol, Katherine B Winfree, Gebra Cuyun Carter, et al.
Oncotargets and Therapy|December 13, 2016
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancerEdward B Garon, Jeffrey D Neidhart, Nashat Y Gabrail, et al.
Lung Cancer Management|May 8, 2013
The role of estrogen, progesterone and aromatase in human non-small-cell lung cancerNadiyah Kazmi, Diana C Márquez-Garbán, Lilia Aivazyan, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2022
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationshipKazuhiko Nakagawa, Edward B Garon, Ling Gao, et al.
Pageof 21